Background: Given that anorexia nervosa (AN) is a life-threatening mental disorder and has poor clinical outcomes, novel effective treatments are warranted, especially for severe and persistent cases.
Introduction
Anorexia nervosa (AN) is associated with the highest mortality rate of all psychiatric disorders and is one of the most challenging mental diseases to treat [1, 2] . The lifetime prevalence of AN in females ranges from 1.2 to 2.2%, also representing one of the most common psychiatric disorders in young girls aged 15-19 years [1] [2] [3] .
Nonetheless, AN often persists into adulthood as it is unresponsive to pharmacotherapy. According to the Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-5), AN is characterized by restrained food intake, which results in a significantly lower body weight than that expected according to a patient's age, sex, and height; intense fear of weight gaining and relentless drive for thinness; as well as a distorted self-perception of body image and weight. However, weight-loss-related behaviors can also include purging and excessive physical activity.
Indeed, two subcategories of AN can be specified, i.e., the restricting (R-AN) and binge-eating/purge (BP-AN) subtypes [4] . Furthermore, psychiatric comorbidities, such as obsessive-compulsive disorders (OCDs) and mood or anxiety disorders, are usually observed in patients with AN [5, 6] . Suicide and medical complications are the major causes of mortality in patients with AN [1, 2] .
Robust evidence supporting the efficacy of psychological and pharmacological therapies is lacking, especially for adult AN patients [7] . In fact, about 20% of patients fail to respond to current psychotherapies and adjuvant pharmacological treatments, thus remaining chronically ill [8] . Nonetheless, pharmacotherapy is the most common treatment option in China and medications are frequently used to relieve the associated symptoms of AN, including anxiety, depression, obsessions, and compulsions.
Deep brain stimulation (DBS) is an invasive neurosurgical intervention that involves the continuous delivery of electrical impulses (through typically 2 bilaterally implanted electrodes) to the critical brain area believed to drive the pathological activity. Given that DBS was proven to be a safe and highly effective treatment for controlling the motor symptoms associated with movement disorders [9] , clinicians have taken considerable interest in employing DBS in some circuit-based psychiatric disorders, such as major depression [10] and AN [11] [12] [13] [14] . Previously, we suggested the DBS of the nucleus accumbens (NAcc), i.e., a subcomponent of the ventral striatum, to be a relatively safe and valuable option for weight restoration in patients with refractory AN [12] . This brain area was particularly chosen considering its crucial role in the reward circuitry [15] and the emerging evidence from resting-state and task-based functional imaging suggesting abnormalities in reward processing in AN patients [16] . Similarly, we here present a long-term follow-up study of a more extensive cohort of patients with refractory AN. Specifically, the safety and feasibility as well as the effects of NAcc-DBS on weight restoration were evaluated, while taking AN-related psychiatric comorbidities into consideration.
Methods

Participants
While this study was approved by the Ethics Committee of the Ruijin Hospital of the Shanghai Jiao Tong University School of Medicine, all the studies here mentioned were conducted in accordance with the Declaration of Helsinki. The patients recruited in the present study were referred by either psychiatrists or gastroenterologists of our hospital or other facilities. Thereafter, they were individually assessed by a group of psychiatrists, neurosurgeons, and neurologists, according to the inclusion criteria 
Surgical procedure
The NAcc-DBS procedure described in our previous study was employed [12] .
Briefly, a Leksell stereotactic frame (Elekta, Inc., Stockholm, Sweden) was mounted on the patient's head under either local anesthesia or mild sedation. Following frame placement, preoperative MRI was immediately performed (1.5 T; General Electric, Madison, WI) for the identification of nuclei accumbens, determined by high-resolution axial and coronal T2-weighted and inversion recovery images.
Subsequently, the medial and most ventral part of the NAcc was bilaterally targeted for implantation of the electrodes (Model 3387; Medtronic, Inc., Minneapolis, MN).
These were located approximately 3 mm anterior to the anterior commissure, 4 mm from the midline, and 6 mm below the anterior commissure-posterior commissure line.
The trajectory was 10-15 degrees lateral in the coronal plane and 45 degrees anterior in the sagittal plane. Thereafter, bilateral C-shaped scalp incisions were performed, and burr holes were bilaterally placed anterior to the coronal suture and approximately 3-4 cm from the midline. Consequently, the dura was opened at the predicted entrance trajectory, and the electrodes were implanted at the target coordinates.
Successively, macrostimulation (180 Hz, 90 µs, 1-8 V) was conducted to confirm successful electrode placement and to evaluate potential side effects. Finally, the electrodes were connected via subcutaneous wires to implantable pulse generators (Soletra, Medtronic, Inc. USA) placed subcutaneously in the subclavicular area.
Patients were under general anesthesia for this part of the operation. Postsurgery MRI was performed 7 days after the surgery (Fig. 1 ).
Stimulation adjustment
The stimulator was not activated until patients were readmitted to the hospital 1 or 2 weeks after the operation. For consistency, the programming of all IPG devices was executed by the same neurosurgeon (Dr. Li). Typically, the closest contacts to the anatomic NAcc (identified on the postsurgery MRI images) were chosen as initial stimulating contacts. The target contacts were activated bilaterally at 2.5 V, 160 Hz, and 120 µs (i.e., pulse width) for all patients. Due to a lack of references regarding the initial stimulation parameters of NAcc in AN patients, we referred to the parameters commonly used in our center for both movement and mental disorders, as well as to those reported in the literature [18, 19] . Briefly, while the voltage was gradually increased to a controllable range, patients were asked about their feelings. Furthermore, the voltage threshold above which unsatisfactory feelings occurred in subjects was recorded for each patient, and the final voltage was set to about one half of such threshold. The stimulation parameters were then kept unchanged for approximately 1 month to determine both the therapeutic effects and potential complications. Indeed, transient side effects, including flush and sweating, could be rapidly relieved by parameter adjustment. Patients were readmitted several times (3 times on average) for re-programming. The optimal stimulation parameters were the following: 2.5-4.0 V, 160-180 Hz, and 120-150 µs. Medication changes were not performed during the first 6 months following the surgery. 7 
Clinical evaluation
Both the body mass index (BMI) and the psychometric data were collected from all patients at each follow-up point. The BMI was calculated using the following formula: 
Results
Demographic data
Of 40 potentially eligible patients referred to our department, 29 female patients with refractory AN accepted to undergo bilateral NAcc-DBS between January 2010 and January 2015. All presented a clinically significant history of nonresponse to treatment, and 28 reported comorbidities (9, 7, and 12 subjects had OCD, (Y-BOCS score >25) severe anxiety, (HAMA score ≥ 29) and major depressive disorder (HAMD score ≥ 35), respectively). Only data from 28 patients were analyzed, given that 1 subject did not complete the full 2-year follow-up because of nonmedical issues.
Patients were aged between 18 and 32 years (22.8 ± 4.1 years), and they all had amenorrhea. The baseline BMI prior to surgery was 13.01 ± 1.86 kg/m 2 . Detailed demographic data of these patients are summarized in Table 1 .
Complications and safety
The most common short-term side effect observed was pain at the incision sites (n = 22), which usually disappeared 3-4 days following the surgery. In addition, transient side effects related to the programming of the device were reported, including flush and sweating, and rapidly relieved by parameter adjustment. Finally, one patient had her device explanted at 18 months from the surgery considering that she experienced device rejection. Cases of either intracranial hematoma or infection at the incision sites were not observed. Similarly, fatalities were not reported in the present study.
Impact on BMI
Compared to presurgical levels, the mean BMI significantly increased at the 6-month Nonetheless, 11 patients presented a lower-than-normal BMI at the end of the investigation (Table 2; Figure 2 ).
Impact on psychometric measures
With regards to the mood and anxiety symptoms (Table 2, Figure 2 ), the mean Y-BOCS score significantly improved during the 6-month review (13.29 ± 6.65, t = -5.302, p < 0.001) and was maintained at the 2-year follow-up (13.04 ± 9.61, t = -5.724, p < 0.001). Similarly, both the anxiety and depression measures (HAMA and HAMD, respectively) significantly ameliorated during the 6-and 24-month follow-ups. In contrast, the NAcc-DBS seemed to hardly impact patients' cognitive ability, as evaluated by the MMSE. Finally, a considerable improvement in social functioning was here identified during the 2-year follow-up, as indicated by the SDSS score (Table 2, Figure 2 ).
NAcc-DBS in patients with R-AN and BP-AN: a post-hoc analysis
Given that 11 patients did not satisfactorily respond to NAcc-DBS, as assessed at the 2-year review, we further compared the R-AN and BP-AN subgroups ( Table 3) . Of the 28 patients who completed the full 2-year follow-up, 13 were diagnosed with R-AN and 15 with BP-AN. While an absence of statistical significance in demographic data between the 2 subgroups was noted at the start of the study, the same was true for both the BMI and psychometric scale scores (except for the MMSE score). However, the BMI of the BP-AN subgroup (16.20 ± 3.02 kg/m 2 ) was significantly lower than that of the R-AN subgroup (19.66 ± 3.29 kg/m 2 ) at the 2-year review (p =0.009). This suggests the NAcc-DBS to be less effective for weight restoration in BP-AN patients. In contrast, the presurgical MMSE score of patients with R-AN (26.46 ± 1.33) was better than that of subjects with BP-AN (24.87 ± 1.25) (p =0.003), even though this difference disappeared after the NAcc-DBS at the 6-and 24-month follow-ups.
Discussion
AN is a severe mental disorder with the highest mortality rate of all psychiatric disorders. Long-lasting malnutrition may lead to serious physical complications, such as liver damage, electrolyte disturbances, and multiple organ failure [7] . Given that only few nonsurgical treatments are effective for adult AN patients, we introduced in a previous study the use of chronic NAcc-DBS as a beneficial treatment option [12] .
Similarly, Lipsman et al. recently reported that continuous DBS of the subcallosal cingulate may promote weight restoration and alleviate the associated psychiatric symptoms patients with treatment-resistant AN during a 1-year follow-up [14] . To the best of our knowledge, the current study is the first longitudinal investigation to assess the long-term effects of NAcc-DBS in a larger patient cohort with refractory AN.
A consensus on the definition of severe and enduring AN is yet to be provided, however, it is warranted to inform both research and clinical practice [20] . In this study, we recruited patients according to the following criteria proposed to be Considering that the cutoff values defining severe and enduring AN may range from 3 to 10 years across studies [20] [21] [22] , we could have prolonged the presurgical illness duration to exclude the possibility of natural recovery. However, this may also have exposed patients to life-threatening conditions. Indeed, while nutritional support, such as the nasogastric feeding tube, is not suitable for outpatient care, long-term inpatient care may also largely impact patients' social functioning. Thirdly, a failure in the multimodal management of the disorder (including pharmacotherapy for 12 weeks and psychological therapy for at least 3 months) was considered as treatment-resistant in this study. A few effective psychological and pharmacological therapies exist, such as the family-based treatment and the Maudsley family therapy [23] . However, although they are well-established for the treatment of adolescent AN, their efficacy in the adult AN population is limited. To date, robust evidence supporting the efficacy of psychological and pharmacological therapies for adult AN patients is lacking [7] .
Moreover, given the discrepancy on the accessibility of psychotherapeutic interventions specific to eating disorders in China, a large proportion of our patients did not receive appropriate early-stage psychological interventions.
The NAcc has long been considered as a crucial node within the reward circuitry.
Emerging evidence further indicated it to play a key role in action selection associated with goal-directed behavior, rendering it more efficient [24] . Abnormalities within the NAcc have indeed been implicated in a variety of psychiatric disorders, and NAcc-DBS was previously used for the treatment of OCD [25] , MDD [26] , and anxiety [27] , showing great potential with numerous prospective applications.
Consistent with previous reports [25] [26] [27] , our results demonstrated that NAcc-DBS is effective for relieving AN-associated anxious, depressive, and obsessive-compulsive symptoms. Interestingly, while the BMI consistently increased during the 2-year follow-up period, improvement in the comorbid mood disorders seemed to reach a plateau at the 6-month review. In concordance with these results, we suggest that even partial reversions of malnutrition, as observed in the 6-month review, could result in rapid improvements in the mood comorbidities [28] . Furthermore, a limited amelioration in the mean MMSE score after NAcc-DBS was observed. This might be explained by the ceiling effect, as patients' cognitive ability was relatively preserved prior to the surgery.
Previously, we reported a large-cohort longitudinal study indicating that capsulotomy facilitates weight restoration in patients with refractory AN without causing significant cognitive deficits [29] . With the results obtained from the present study, we propose that both capsulotomy and DBS are effective in improving BMI as well as mood, anxiety, affective regulation, and OCD in patients with refractory AN. This may, at least in part, be explained by the close anatomical and functional connections between the NAcc and the anterior limb of the internal capsule [30] . However, future studies with a larger cohort should be conducted to confirm our hypothesis.
Interestingly, our post-hoc analysis revealed the NAcc-DBS to be less effective in patients with BP-AN than in those with R-AN. Similarly, a previous study on SCC-DBS by Lipsman et al. showed the mean BMI of 5 patients with BP-AN (15.68 ± 1.70 kg/m 2 ) to be lower than that of 9 subjects with R-AN (18.26 ± 3.83 kg/m 2 ) at the 1-year follow-up (p = 0.185) [14] . Indeed, patients with BP-AN exhibited higher levels of the core AN psychopathology, such as the restrained food intake, shape/weight concerns, and eating concerns as compared to subjects with R-AN [31] .
Moreover, the former report greater neurocognitive impairments than the latter [32] , which is consistent with our result on the significantly lower presurgical MMSE score seen in patients with BP-AN. Additionally, the electrolyte disturbances are reported to be more pronounced in BP-AN, which could have an additive effect on the cognitive impact of malnutrition. [33] Therefore, we suggest that DBS might be more suitable for the treatment of refractory R-AN, as opposed to BP-AN. However, further large sample-based prospective studies are needed to provide additional evidence on the matter.
Limitations
The present study has some limitations. Given that neither a blinded sham stimulation nor blinded assessments were conducted, a placebo effect explaining our findings cannot be excluded. In addition, due to the lack of controls, we are unable to determine whether the observed improvement was a result of the natural course of the illness. Indeed, the major focus of this study was the general safety profile of DBS and its effect on BMI and other concomitant disorders. Therefore, our clinical evaluation only included the most important outcome criteria in AN, such as the BMI and the observer-rated scales of depression, anxiety, and social disability. For this reason, eating disorder-specific scales (e.g., Eating Attitudes Test [EAT-26] and Eating Disorder examination questionnaire [EDE-Q 6.0]) and cognitive (e.g., executive 13 functioning, central coherence, and theory of mind) and endocrinological measurements were not included in the present study. Finally, although our study analyzed the largest cohort reported to date for a DBS study in patients with refractory AN, supportive evidence from well-controlled multicenter investigations is required.
Conclusions
NAcc-DBS is safe and effective for normalizing body weight and improving comorbid psychiatric symptoms in patients with refractory AN without causing significant cognitive deficit. In addition, although NAcc-DBS seems to be more suitable for patients with refractory R-AN, strict inclusion criteria must be applied considering surgery-related complications. Given the limitations of our study (mainly the lack of controls and the absence of a double-blinded design), concluding remarks
are not yet possible. Therefore, future studies with more appropriate experimental designs are warranted to further support our claims.
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